Digestion of IgG Below the Hinge Region
CD BioGlyco provides systematic and one-stop Antibody Digestion Services for the digestion of IgG below the hinge region and ensures the continuity and transparency of the experimental process.
The Structure of F(ab')2 and Fc Fragments
It is very useful to study or exploit the partial activity of immunoglobulins without interference from other molecular fragments. Immunoglobulin molecules are selectively cleaved into fragments with discrete features.
F(ab')2 fragments refer to two antigen-binding F(ab) moieties linked together by disulfide bonds. Compared to whole IgG molecules, F(ab')2 fragments are smaller, allowing better penetration into tissues and facilitating better antigen recognition in IHC. The use of F(ab')2 fragments also avoids non-specific binding to specific receptors (Fc receptors) or specific proteins (Protein A/G) on living cells.
Fig.1 The structure of F(ab')2 fragments. (Bates & Power, 2019)
The fragment crystalline region (Fc region) mainly binds to Fc receptors on the cell surface and interacts with some proteins of the complement system. This property is closely related to the activation of the immune system by antibodies. Therefore, glycosylation of Fc fragments is critical for Fc receptor-mediated activity. In the IgG antibody isotype, the Fc region consists of two identical protein fragments derived from the second and third constant domains of the two heavy chains of the antibody.
Key Technologies
Our core technology is the use of IdeS (Immunoglobulin G-degrading enzyme from Streptococcus pyogenes). IdeS is a cysteine protease that specifically cleaves all subclasses of human IgG below the hinge region, generating F(ab')2 fragments and intact Fc fragments. We also utilize a suite of other proteases and custom protocols to accommodate various IgG subclasses, species, and unique project requirements, ensuring that every digestion is optimized for maximum yield and fragment integrity.
Digestion of IgG Below the Hinge Region at CD BioGlyco
CD BioGlyco provides an enzyme that digests IgG at a specific site below the hinge region under physiological reaction conditions, with optimal activity at 37°C. Digestion produces a homogeneous library of F(ab')2 and Fc/2 fragments. As far as we know IgG is the only substrate. In general, IgG is digested within half an hour, but not over-digested with longer incubation times.
Our high specific enzyme can digest all subclasses of human, monkey, rabbit, and sheep IgG, but it has limited activity on mouse IgG2a and IgG3. We will introduce related services on another page: Digestion of Mouse IgG2a and IgG3 Below the Hinge Region.
- Project Design
Clarify the core objectives of your project first: the specific IgG subtype targeted for digestion, the type of fragment you aim to obtain, and the intended downstream use scenarios. On this basis, determine the most suitable digestion approach, and screen out the optimal protease type and matching reaction parameters (such as temperature, pH, and reaction time).
- IgG Preparation
You may provide purified IgG samples directly, or we can support you in completing the IgG purification process. Subsequently, we will conduct a strict quality inspection to confirm two critical indicators of the initial material: the structural integrity and concentration.
- Enzymatic Digestion
We employ specific enzymes (e.g., IdeS protease) to carry out cleavage reactions. Throughout the process, reaction conditions are strictly monitored and controlled.
- Fragment Purification and Isolation
After the digestion reaction, we adopt efficient separation methods (e.g., Protein A chromatography) to isolate the Fc fragment. The core goal of this step is to completely remove impurities, including F(ab')2 fragments generated during digestion, unreacted intact IgG, and residual protease, thereby obtaining high-purity Fc fragments.
- Characterization
To fully confirm the quality of the prepared Fc fragment, we combine multiple analytical technologies for comprehensive detection: sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is used to verify molecular weight and purity; mass spectrometry (MS) helps confirm structural identity; in addition, other professional bioanalytical methods are applied to further ensure the overall integrity and usability of the Fc fragment.
Workflow
Publication Data
Journal: Antibodies
IF: 2.7
Published: 2019
Results: The review found that smaller antibody fragments have several advantages over full-length mAbs, including lower production costs, higher yields, and better tissue penetration due to their small size. These properties allow them to reach difficult-to-access epitopes and are particularly useful for applications like cancer immunotherapy. These new formats offer exciting opportunities to expand the use of antibodies into previously challenging areas, such as developing oral antibodies for neurological diseases or targeting intracellular molecules.
Applications
- Modifying Fc glycans fine-tunes effector functions, leading to the development of new therapeutics with enhanced potency and safety.
- Using defined Fc fragments significantly improves the specificity and sensitivity of immunoassays, enabling the development of more reliable diagnostic tools.
- High-quality, homogeneous Fc fragments are essential for structural studies, helping to elucidate the role of glycosylation in antibody structure and function.
- Our fragments provide a unified platform for detailed glycan analysis, helping researchers understand the complex relationship between glycan structure and biological activity.
Advantages of Us
- One-stop service for digestion of IgG below the hinge region
- Customize experimental programs according to different research needs
- The high specificity of the enzymes used
- Responses under physiological conditions allow the preservation of the immunoreactivity of IgG
- Detailed and reliable after-sales service
Frequently Asked Questions
CD BioGlyco has an advanced Glycoengineering Platform in glycoscience. Our professional research teams allow us to provide you with high-quality services for the digestion of IgG below the hinge region. If you are interested in our services, please contact us for more details without any hesitation.
Associated Services
Generate specific glycan-modified proteins or conjugates for your research needs.
Engineer and produce antibodies with specific Fc regions, including those with custom glycosylation sites.
Characterize the glycan structures on your Fc fragments to understand their impact on function.
Reference
- Bates, A.; Power, C.A. David vs. Goliath: the structure, function, and clinical prospects of antibody fragments. Antibodies. 2019, 8(2): 28. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




